EBV-induced post transplant lymphoproliferative disorders: A persisting challenge in allogeneic hematopoetic SCT

Bone Marrow Transplantation

Volumn 49, Issue 2, 2014, Pages 163-167

  Rasche, L ^a   Kapp, M ^a   Einsele, H ^a   Mielke, S ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Allogeneic hematopoetic; EBV; Post transplant lymphoproliferative disorders

Indexed keywords

EPSTEIN-BARR VIRUS INFECTIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; RISK FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 84893792563     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2013.96     Document Type: Review

References (45)

1. Ruf S, Moser O, Wo?ssmann W, Kreyenberg H, Wagner HJ. Examining the origin of posttransplant lymphoproliferative disorder in a patient after a second allogeneic hematopoeitic stem cell transplantation for relapsed BCR-ABL positive acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2011; 33: 50-54.
2. Reddiconto G, Chiusolo P, Fiorini A, Farina G, Laurenti L, Martini M et al. Assessment of cellular origin and EBV status in a PTLD after double cord blood transplantation. Leukemia 2007; 21: 2552-2554.
3. Gong JZ, Bayerl MG, Sandhaus LM, Sebastian S, Rehder CW, Routbort M et al. Posttransplant lymphoproliferative disorder after umbilical cord blood transplantation in children. Am J Surg Pathol 2006; 30: 328-336.
4. Johansson JE, Remberger M, Lazarevic VLj, Hallbo?o? k H, Wahlin A, Kimby E et al. Allogeneic haematopoietic stem-cell transplantation with reduced intensity conditioning for advanced stage Hodgkin's lymphoma in Sweden: high incidence of post transplant lymphoproliferative disorder. Bone Marrow Transplant 2011; 46: 870-875.
5. Hou HA, Yao M, Tang JL, Chen YK, Ko BS, Huang SY et al. Poor outcome in post transplant lymphoproliferative disorder with pulmonary involvement after allogeneic hematopoietic SCT: 13 years' experience in a single institute. Bone Marrow Transplant 2009; 43: 315-321.
6. Buyck HC, Ball S, Junagade P, Marsh J, Chakrabarti S. Prior immunosuppressive therapy with antithymocyte globulin increases the risk of EBV-related lymphoproliferative disorder following allo-SCT for acquired aplastic anaemia. Bone Marrow Transplant 2009; 43: 813-816.
7. Ocheni S, Kroeger N, Zabelina T, Sobottka I, Ayuk F, Wolschke C et al. EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT. Bone Marrow Transplant 2008; 42: 181-186.
8. Landgren O, Gilbert ES, Rizzo JD, Socie? G, Banks PM, Sobocinski KA et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 2009; 113: 4992-5001.
9. Styczynski J, Einsele H, Gil L, Ljungman P. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis 2009; 11: 383-392.
10. Omar H, Ha?gglund H, Gustafsson-Jernberg A, LeBlanc K, Mattsson J, Remberger M et al. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction. Transpl Infect Dis 2009; 11: 393-399.
11. Sundin M, Le Blanc K, Ringde?n O, Barkholt L, Omazic B, Lergin C et al. The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Haematologica 2006; 91: 1059-1067.
12. Agbalika F, Larghero J, Esperou H, Marais D, Robin M, Fos E et al. Epstein-Barr virus early-antigen antibodies before allogeneic haematopoietic stem cell transplantation as a marker of risk of post-transplant lymphoproliferative disorders. Br J Haematol 2007; 136: 305-308.
13. Islam MS, Anoop P, Gordon-Smith EC, Rice P, Datta-Nemdharry P, Marsh JC. Epstein-Barr virus infections after allogeneic stem cell transplantation: a comparison between non-malignant and malignant hematological disorders. Hematology 2010; 15: 344-350.
14. Carpenter B, Haque T, Dimopoulou M, Atkinson C, Roughton M, Grace S et al. Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumabbased conditioning for allogeneic hematopoietic stem-cell transplantation. Transplantation 2010; 90: 564-570.
15. Chiusolo P, Metafuni E, Cattani P, Piccirillo N, Santangelo R, Manzara S et al. Prospective evaluation of epstein-barr virus reactivation after stem cell transplantation: association with monoclonal gammopathy. J Clin Immunol 2010; 30: 894-902.
16. Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000; 343: 481-492.
17. Yates J, Warren N, Reisman D, Sugden B. A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. Proc Natl Acad Sci USA 1984; 81: 3806-3810.
18. Kalinova L, Indrakova J, Bachleda P. Post-transplant lymphoproliferative disorder. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2009; 153: 251-257.
19. Friedberg JW, Swinnen LJ. Post-Transplant Lymphproliferative Disease in The Lymphomas. Second Edition (Elsevier: Philadelphia, PA, USA, 2006).
20. Diekmann J, Adamopoulou E, Beck O, Rauser G, Lurati S, Tenzer S et al. Processing of two latent membrane protein 1 MHC class I epitopes requires tripeptidyl peptidase II involvement. J Immunol 2009; 183: 1587-1597.
21. Wang D, Liebowitz D, Kieff E, An EBV. membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 1985; 43(3 Pt 2): 831-840.
22. Henderson S, Huen D, Rowe M, Dawson C, Johnson G, Rickinson A. Epstein-Barr virus-coded BHRF1 protein, a viral homologue of Bcl-2, protects human B cells from programmed cell death. Proc Natl Acad Sci USA 1993; 90: 8479-8483.
23. Swerdlow SH, Webber SA, Chadbrun A, Ferry JA. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. (IARC: Lyon, France, 2008).
24. Knowles DM, Cesarman E, Chadburn A, Frizzera G, Chen J, Rose EA et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995; 85: 552-565.
25. Comoli P, Basso S, Zecca M, Pagliara D, Baldanti F, Bernardo ME et al. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am J Transplant 2007; 7: 1648-1655.
26. Muramatsu H, Takahashi Y, Shimoyama Y, Doisaki S, Nishio N, Ito Y et al. CD20-negative Epstein-Barr virus-associated post-transplant lymphoproliferative disease refractory to rituximab in a patient with severe aplastic anemia. Int J Hematol 2011; 93: 779-781.
27. Deeg HJ, Socie G. Malignancies after hematopoietic stem cell transplantation: many questions, some answers. Blood 1998; 91: 1833-1844.
28. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15: 1143-1238.
29. Ahmad I, Cau NV, Kwan J, Maaroufi Y, Meuleman N, Aoun M et al. Preemptive management of Epstein-Barr virus reactivation after hematopoietic stem-cell transplantation. Transplantation 2009; 87: 1240-1245.
30. Blaes AH, Cao Q, Wagner JE, Young JA, Weisdorf DJ, Brunstein CG. Monitoring and preemptive rituximab therapy for Epstein-Barr virus reactivation after antithymocyte globulin containing nonmyeloablative conditioning for umbilical cord blood transplantation. Biol Blood Marrow Transplant 2010; 16: 287-291.
31. Weinstock DM, Ambrossi GG, Brennan C, Kiehn TE, Jakubowski A. Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development. Bone Marrow Transplant 2006; 37: 539-546.
32. Rowe DT, Webber S, Schauer EM, Reyes J, Green M. Epstein-Barr virus load monitoring: its role in the prevention and management of post-transplant lymphoproliferative disease. Transpl Infect Dis 2001; 3: 79-87.
33. Meijer E, Cornelissen JJ. Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients. Curr Opin Hematol 2008; 15: 576-585.
34. Beck R, Westdo? rp I, Jahn G, Scha? fer H, Kanz L, Einsele H. Detection of Epstein-Barr virus DNA in plasma from patients with lymphoproliferative disease after allogeneic bone marrow or peripheral blood stem cell transplantation. J Clin Microbiol 1999; 37: 3430-3431.
35. McIver Z, Stephens N, Grim A, Barrett AJ. Rituximab administration within 6 months of T cell-depleted allogeneic SCT is associated with prolonged life-threatening cytopenias. Biol Blood Marrow Transplant 2010; 16: 1549-1556.
36. Stuhler G, Knop S, Topp MS, Kro? ber SM, Ernemann U, Herrlinger U et al. Intravenously administered rituximab induces remission of EBV associated non Hodgkin lymphoma confined to the brain in a patient after allogeneic stem cell transplantation. Haematologica 2006; 91: ECR01.
37. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010; 115: 925-935.
38. Rooney CM, Smith CA, Ng CY, Loftin SK, Sixbey JW, Gan Y et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92: 1549-1555.
39. Moosmann A, Bigalke I, Tischer J, Schirrmann L, Kasten J, Tippmer S et al. Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells. Blood 2010; 115: 2960-2970.
40. Uhlin M, Okas M, Gertow J, Uzunel M, Brismar TB, Mattsson J. A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation. Cancer Immunol Immunother 2010; 59: 473-477.
41. Barker JN, Doubrovina E, Sauter C, Jaroscak JJ, Perales MA, Doubrovin M et al. Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes. Blood 2010; 116: 5045-5049.
42. Reisner Y, Hagin D, Martelli MF. Haploidentical hematopoietic transplantation: current status and future perspectives. Blood 2011; 118: 6006-6017.
43. Mielke S, McIver ZA, Shenoy A, Fellowes V, Khuu H, Stroncek DF et al. Selectively T cell-depleted allografts from HLA-matched sibling donors followed by low-dose posttransplantation immunosuppression to improve transplantation outcome in patients with hematologic malignancies. Biol Blood Marrow Transplant 2011; 17: 1855-1861.
44. Savani BN, Mielke S, Rezvani K, Montero A, Yong AS, Wish L et al. Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 1216-1223.
45. Leen AM, Bollard CM, Mendizabal AM, Shpall EJ, Szabolcs P, Antin JH et al. Multicenter study of banked third party virus-specific T-cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood (e-pub ahead of print 22 April 2013).